- Europe and International + 33 1 81 69 16 01
- USA and Canada +1 617 682 3624
Cellectis bioresearch to present new tools for the production of therapeutic proteins at the 2010 Cell Line Development and Engineering Conference in Prague.
Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), will present its first results showing that meganuclease engineering can improve the features of a parental cell line used to produce biodrugs. The presentation will be made at the Cell Line Development and Engineering Conference in Prague on March 3, 2010.
“This constitutes further proof of the efficiency of meganucleases in genome customization,” explained Luc Selig, Sales and Marketing Director at Cellectis bioresearch. “Our engineering of biodrug producing cells reveals the potential and the very high specificity of meganucleases”.
Meganucleases are innovative tools that enable targeted modification to DNA to obtain precise and stable modifications in the genome. Cellectis bioresearch’s current products enable targeted gene integration. The results to be presented in Prague broaden the potential range of applications of the technology by demonstrating the ability of a specific meganuclease to knock-out an endogenous gene.&nb